左心室收缩功能障碍即使给予最优化的药物治疗死亡率和不良事件发生率仍很高。心房跟踪的双心室起搏,即心脏再同步治疗(CRT),于2001年获得美国FDA批准用于部分左室收缩功能障碍的病人。该系统评价的目的在于总结CRT用于左心室收缩功能障碍病人的效果、有效性、安全性的现有证据 Left ventricular systolic dysfunction even given the optimal drug treatment mortality and adverse events are still high incidence. Atrial tracking biventricular pacing, cardiac resynchronization therapy (CRT), was approved by the U.S. FDA in 2001 for patients with partial LV systolic dysfunction. The purpose of this systematic review is to summarize the available evidence of efficacy, efficacy, and safety of CRT for patients with left ventricular systolic dysfunction